Intellia Therapeutics to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that management will be participating in the upcoming investor conferences: TD Cowen 46th Annual Health Care ConferenceDate: Tuesday, March 3, 2026Fireside Chat Time: 1:10 p.m.

GlobeNewsWire • 16 hours ago

What's in Store for These 5 Medical Companies This Earnings Season?

IRWD, RXRX, NVAX, VTRS and NTLA gear up for earnings as the Medical sector posts solid sales growth despite a slight profit dip so far.

Zacks Investment Research • Feb 23, 2026

Take the Zacks Approach to Beat the Markets: Intellia, Colgate-Palmolive, Getty in Focus

NTLA, CL and GTY are in focus as Zacks highlights strong 12-week gains and post-upgrade rallies across its Focus List and model portfolios.

Zacks Investment Research • Feb 23, 2026

Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2025 Financial Results and Business Updates

CAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that the company will host a conference call on February 26, 2026, at 8 a.m. ET to discuss its fourth quarter and full-year 2025 financial results and business updates.

GlobeNewsWire • Feb 19, 2026

This Cathie Wood Stock Is Already Up 41% This Year, But Is It a Buy?

Intellia Therapeutics recently announced an important regulatory development. The company estimates a large addressable market for its two leading candidates.

The Motley Fool • Feb 7, 2026

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on February 1, 2026, it awarded inducement grants to six new employees under Intellia's 2024 Inducement Plan as a material inducement to employment.

GlobeNewsWire • Feb 6, 2026

Intellia Therapeutics: 2 Major Catalysts Will Determine Stock's Trajectory In 2026

Intellia Therapeutics is reinstated as a Buy, driven by two late-stage in-vivo gene therapy programs: lonvo-z and nex-z. Key 2026 catalysts are the MAGNITUDE clinical hold decision for ATTR-CM and Phase 3 lonvo-z HAE data readout, both with significant valuation impact. Lonvo-z offers potential for a one-time, functional cure in HAE, with strong efficacy and a manageable safety profile, but market adoption hinges on Phase 3 results.

Seeking Alpha • Feb 5, 2026

Intellia Therapeutics (NTLA) Surges 6.3%: Is This an Indication of Further Gains?

Intellia Therapeutics (NTLA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Investment Research • Jan 28, 2026

NTLA Stock Up More Than 6% as FDA Lifts ATTRv-PN Study Clinical Hold

Intellia jumps over 6% after the FDA lifts the clinical hold on the MAGNITUDE-2 study, clearing a path to resume dosing of nex-z in ATTRv-PN.

Zacks Investment Research • Jan 28, 2026

US FDA lifts clinical hold on Intellia's nerve disease trail

Intellia Therapeutics said on Tuesday that the U.S. Food and Drug Administration has lifted a clinical hold on one of its gene therapy late-stage trial, allowing the company to resume testing its experimental drug for a rare nerve disease.

Reuters • Jan 27, 2026